Global Post-Traumatic Stress Disorder Therapeutics Industry to Reach $10.68 Billion by 2026 - Antidepressants Play a Stellar Role

Dublin, July 02, 2018 (GLOBE NEWSWIRE) -- The "Global Post-Traumatic Stress Disorder Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

The global post-traumatic stress disorder therapeutics market is projected to reach US$ 10,679.5 Mn by 2026, expanding at a CAGR of 4.5% from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market.

Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.

As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals.

The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.

Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.

Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period.

However, Europe will be clearly challenged by the Asia Pacific by end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence. There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.

Key Topics Covered

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.2. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Post-Traumatic Stress Disorder Therapeutics Market Overview, 2016 - 2026 (US$ Mn)
3.1. Overview
3.2. Market Drivers
3.2.1. Growing Events of Violence and Wars
3.3. Challenges
3.3.1. Lack of Timely Diagnosis and Access to Care
3.3.2. Risk of Side Effects
3.4. Opportunities
3.4.1. Promising Pipeline Candidates
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Market Competition Assessment, 2017

Chapter 4. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Antidepressants
4.2.1. SSRIs
4.2.2. SNRIs
4.2.3. MAO Inhibitors
4.2.4. Tricyclic Antidepressants
4.3. Anti-anxiety Drugs
4.3.1. Beta-blockers
4.3.2. Benzodiazepines
4.4. Other Drug Classes
4.4.1. Alpha-1 & Alpha-2 Receptor Antagonists
4.4.2. Atypical Antipsychotics
4.4.3. Anticonvulsants
4.5. Pipeline Candidates (Qualitative Information)
4.5.1. SRX 246 (Phase II)
4.5.2. BNC 210 (Phase II)
4.5.3. Tonmya (Phase II)

Chapter 5. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. North America
5.2.1. North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.2.3. North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.2.4. North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.2.5. North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.2.5.1. U.S.
5.2.5.2. Canada
5.3. Europe
5.3.1. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.3.3. Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.3.4. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.3.5. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.3.5.1. U.K.
5.3.5.2. Germany
5.3.5.3. Rest of Europe
5.4. Asia Pacific
5.4.1. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.4.3. Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.4.4. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.4.5. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.4.5.1. Japan
5.4.5.2. China
5.4.5.3. Rest of APAC
5.5. Latin America
5.5.1. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.5.3. Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.5.4. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.5.5. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.5.5.1. Brazil
5.5.5.2. Mexico
5.5.5.3. Rest of Latin America
5.6. Middle East & Africa
5.6.1. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.6.2. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.6.3. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.6.4. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.6.5. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016 - 2026 (US$ Mn)
5.6.5.1. GCC
5.6.5.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. GlaxoSmithKline plc
6.3. Otsuka Pharmaceutical Co., Ltd
6.4. Novartis AG
6.5. AstraZeneca Plc
6.6. Azevan Pharmaceuticals, Inc.
6.7. Bionomics Ltd.
6.8. Tonix Pharmaceuticals Holding Corp.
6.9. Apotex, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/v5bxxn/global?w=12